Chemotherapy of Advanced and Relapsed Squamous Cell Cancer of the Head and Neck with Split-Dose Cisplatinum (DDP), 5-Fluorouracil (Fura) and Leucovorin (CF)

  • T. M. Loeffler
  • J. Lindemann
  • H. Luckhaupt
  • K. G. Rose
  • T. U. Hausamen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)


58 patients with locally advanced or relapsed squamous cell heal and neck cancer were treated on 5 consecutive days with DDP 20 mg/m2/d IV-push, followed by CF 100 mg/m2/d IV-bolus and Fura 400 mg/m2/d IV-push 60 minutes later. Treatment was recycled on day 22(−29), according to toxicity. CF was added to the widely used DDP/Fura combination, because recent studies showed enhancement of Fura-activity by CF. 45/58 patients had no prior therapy and 13/58 pts were relapsed after chemotherapy and/or radiation therapy. All patients were evaluable for toxicity and response. After 3 courses of induction chemotherapy 23/45 pts in the previously untreated group had a complete response (CR); 20/45 a partial response(PR), 2/45 were restaged as no change (CR + PR: 95%). Induction chemotherapy was followed by radical surgery and postoperative radiation therapy. In the pretreated group 4/13 pts had a complete response; 6/13 a partial response; no change in 3/13 pts. Median duration of remission (MDR) has not been reached in the primarily untreated group, whereas in pretreated patients the MDR was 3.8 months (range 2.3–11.7 months). Hematologic and gastrointestinal toxicity was substantial but manageable and therapy was performed on an outpatient basis. The combination of DDP, CF and Fura has high activity in untreated and pretreated head and neck cancer patients. The obtained results are comparable to the widely used DDP/Fora continuous infusion regimen.


Neck Cancer Induction Chemotherapy Untreated Group Neck Cancer Patient Pretreated Patient 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rooney M, Kish J, Jacobs J, et al: Improved complete response rate and survival in advanced head and neck cancer after three course induction therapy with 120 hour 5-FU infusion and Cisplatinum. Cancer 55: 1123–1128 (1985)PubMedCrossRefGoogle Scholar
  2. 2.
    Kish JA, Weaver A, Jacobs J, et al: Cisplatinun and 5-Fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53: 1819–1824 (1984)PubMedCrossRefGoogle Scholar
  3. 3.
    Kish JA, Ensley JF, Jacobs J et al: A randanized trial of Cisplatinum (CACP) + 5-Fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56: 2740–2744 (1985)PubMedCrossRefGoogle Scholar
  4. 4.
    Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-Fluorouracil. Cancer Res. 41: 3288–3295 (1981)PubMedGoogle Scholar
  5. 5.
    Yin MB, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to activity of 5-Fluorouracil. Mol. Pharmacol. 23: 190–197 (1984)Google Scholar
  6. 6.
    Danenberg PV, Denenberg KD: Effect of 5,10-ffethylenetetrahydrofolate and the dissociation of 5-fluoro-2’-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry 17: 4018–4024 (1978)PubMedCrossRefGoogle Scholar
  7. 7.
    Iockshin A., Danenberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyundylate binding of human thymidylate synthetase. Biochem. Pharmacol. 30: 247–257 (1980)CrossRefGoogle Scholar
  8. 8.
    Scanlon KJ, Nee Dels C, Lu Y, et al: Biochemical basis for Cisplatinum and 5-Fluorouracil synergism in human tumors. Proc. Pm. Assoc. Cancer. Res., 26: 1156 (1986)Google Scholar
  9. 9.
    Machover D, Goldscianidt E, Chollet P et al: Treatment of advanced colorectal and gastric adenocarcinana with 5-FU and high-dose Folinic Acid. J. Clin. Oncol. 4: 685–696 (1986)PubMedGoogle Scholar
  10. 10.
    Marini G, Simoncini E, Zaniboni A, et al: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advance breast cancer: An update. Oncology 44: 336–340 (1987)PubMedCrossRefGoogle Scholar
  11. 11.
    Bertrand M, Doroshcw JH, Multhauf P, et al: High-dose continuous infusion folinic acid and 5-fluorouracil in patients with advanced colorectal cancer. A phase II study. J. Clin. Oncol. 4: 1058–1061 (1986)PubMedGoogle Scholar
  12. 12.
    Allegra CJ, Chabner BA, Sholar PW et al: Preliminary results of a phase-II-trial for the treatment of metastatic breast cancer with 5-Fluorouracil and Leucovorin. NCI Monographs, 5: 199–202 (1987)PubMedGoogle Scholar
  13. 13.
    Vokes EE, Choi KE, Schilsky RL, et al: Cis-Platin, Fluorouracil and high dose Leucovorin for recurrent or metastatic head and neck cancer. J. Clin. Oncol. 6: 618–626 (1988)PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • T. M. Loeffler
    • 1
  • J. Lindemann
    • 2
  • H. Luckhaupt
    • 2
  • K. G. Rose
    • 2
  • T. U. Hausamen
    • 1
  1. 1.Department of MedicineMedical Center DortmundDortmundWest Germany
  2. 2.Department of Oto-LaryngologyMedical Center DortmundDortmundWest Germany

Personalised recommendations